Yu-Wen Chang, DO
Family Practice · Menlo Park
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 8 years
- Touro Un College of Osteopathic Medicine, Vallejo, 2018
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: 058123 · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (650) 498-6500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$90,127
Medicare paid this office $90,127 for 201 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 155 | $28,815 | $103 |
| Long return visit (40+ min) | 66 | $14,356 | $154 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 83 | $12,706 | $153 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 21 | $6,079 | $289 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 165 | $4,619 | $14 |
See all 15 services
| Return visit (30+ min) | 155 | $28,815 | $103 |
| Long return visit (40+ min) | 66 | $14,356 | $154 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 83 | $12,706 | $153 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 21 | $6,079 | $289 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 165 | $4,619 | $14 |
| New patient visit (45+ min) | 33 | $4,243 | $129 |
| Influenza vaccine split virus, preservative free | 43 | $3,479 | $81 |
| New patient visit (60+ min) | 16 | $2,836 | $177 |
| Sarscv2 vac 30mcg trs-suc im | 18 | $2,757 | $145 |
| Sarscov2 vac 50 mcg/0.5ml im | 14 | $2,172 | $155 |
| Short return visit (20+ min) | 26 | $1,948 | $72 |
| Admn sarscov2 vacc 1 dose | 32 | $1,702 | $52 |
| Administration of influenza virus vaccine | 44 | $1,682 | $38 |
| Administration of pneumococcal vaccine | 21 | $803 | $38 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 11 | $662 | $51 |
Who their Medicare patients are
201 Original Medicare patients in 2024. Average age 74 · Women 62% · Also on Medicaid 8% · Health risk score 1.00. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 57% · Diabetes 23% · Coronary heart disease 22% · Cancer 16% · Depression 14% · Chronic kidney disease 13% · Atrial fibrillation 9% · Heart failure 8% · COPD 7%.
The office billed $315,524, Medicare allowed $116,465 and paid $90,127; for 1,109 services of 28 kinds; $14,848 of it was for drugs given in the office and $75,279 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 201 | 1,109 | 74 | 1.00 | $315,524 | $90,127 |
| 2023 | 155 | 617 | 73 | 1.07 | $252,202 | $74,806 |
| 2022 | 105 | 386 | 73 | 0.80 | $148,147 | $41,867 |
| 2021 | 23 | 58 | 73 | 0.85 | $21,681 | $5,283 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 107 | $22,318 | $116 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 56 | $15,837 | $283 |
| Long return visit (40+ min) | 37 | $7,420 | $169 |
| New patient visit (45+ min) | 48 | $6,625 | $138 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 41 | $6,270 | $153 |
| New patient visit (60+ min) | 25 | $5,082 | $203 |
| Influenza vaccine split virus, preservative free | 37 | $2,661 | $72 |
| Administration of pneumococcal vaccine | 56 | $2,032 | $36 |
| Short return visit (20+ min) | 19 | $1,884 | $82 |
| Administration of influenza virus vaccine | 39 | $1,415 | $36 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 19 | $271 | $14 |
2022: 11 services
| Return visit (30+ min) | 67 | $12,809 | $110 |
| New patient visit (45+ min) | 55 | $7,207 | $131 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 16 | $4,454 | $278 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | $2,910 | $153 |
| Long return visit (40+ min) | 16 | $2,692 | $168 |
| Influenza vaccine split virus, preservative free | 33 | $2,259 | $68 |
| Pneumococcal vaccine, 23-valent | 14 | $1,865 | $133 |
| Administration of influenza virus vaccine | 33 | $1,190 | $36 |
| Administration of pneumococcal vaccine | 30 | $1,091 | $36 |
| Short return visit (20+ min) | 13 | $1,042 | $80 |
| New patient visit (30+ min) | 13 | $937 | $72 |
2021: 1 service
| New patient visit (45+ min) | 17 | $2,195 | $129 |
Medicaid work
$21,602 in 2019
Medicaid paid $21,602 for 188 billed services this clinician did in 2019, up to 56 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 188 | $21,602 |
| 2019 | 188 | 1 | 56 | $21,602 |
Drugs they prescribed that Part D paid
$123,348
Pharmacies billed $123,348 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,234 generic and fewer than 11 brand-name prescriptions · $123,348 in drug cost · 41 antibiotic prescriptions to 27 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 14 | $37,033 | $2,645 |
| Eliquis | 16 | $22,753 | $1,422 |
| Atorvastatin | 147 | $1,376 | $9 |
| Telmisartan | 11 | $1,297 | $118 |
| Levothyroxine | 71 | $1,113 | $16 |
See all 30 drugs
| Ozempic | 14 | $37,033 | $2,645 |
| Eliquis | 16 | $22,753 | $1,422 |
| Atorvastatin | 147 | $1,376 | $9 |
| Telmisartan | 11 | $1,297 | $118 |
| Levothyroxine | 71 | $1,113 | $16 |
| Rosuvastatin | 57 | $685 | $12 |
| Olmesartan Medoxomil | 31 | $676 | $22 |
| Losartan | 55 | $631 | $11 |
| Amlodipine Besylate | 109 | $561 | $5 |
| Hydroxyzine | 21 | $540 | $26 |
| Tamsulosin | 36 | $506 | $14 |
| Montelukast | 33 | $410 | $12 |
| Omeprazole | 23 | $389 | $17 |
| Synthroid | 15 | $339 | $23 |
| Metoprolol | 12 | $291 | $24 |
| Escitalopram | 13 | $262 | $20 |
| Trazodone | 16 | $251 | $16 |
| Albuterol Sulfate Hfa | 17 | $245 | $14 |
| Zolpidem | 32 | $233 | $7 |
| Metformin | 27 | $226 | $8 |
| Fluticasone Propionate | 11 | $206 | $19 |
| Atenolol | 11 | $194 | $18 |
| Metformin Hcl Er | 28 | $193 | $7 |
| Sertraline | 12 | $188 | $16 |
| Allopurinol | 15 | $165 | $11 |
| Alendronate | 27 | $161 | $6 |
| Lisinopril | 21 | $137 | $7 |
| Pravastatin | 15 | $122 | $8 |
| Simvastatin | 20 | $94 | $5 |
| Azithromycin | 12 | $75 | $6 |
Year by year
| 2024 | 1,365 | 212 | None | None | $123,348 |
| 2023 | 751 | 153 | 0% (0) | None | $46,948 |
| 2022 | 389 | 76 | 0% (0) | None | $26,387 |
| 2021 | 251 | 46 | None | None | $38,964 |
| 2020 | 165 | 29 | 0% (0) | None | $24,472 |
| 2019 | 128 | 21 | 0% (0) | None | $15,992 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Atorvastatin | 88 | $1,340 | $15 |
| Telmisartan | 17 | $947 | $56 |
| Amlodipine Besylate | 48 | $804 | $17 |
| Levothyroxine | 33 | $616 | $19 |
| Losartan | 29 | $482 | $17 |
| Metformin | 32 | $476 | $15 |
| Tamsulosin | 12 | $407 | $34 |
| Rosuvastatin | 20 | $381 | $19 |
| Olmesartan Medoxomil | 17 | $345 | $20 |
| Alendronate | 20 | $291 | $15 |
| Omeprazole | 14 | $257 | $18 |
| Montelukast | 18 | $197 | $11 |
| Duloxetine | 13 | $176 | $14 |
| Zolpidem | 15 | $146 | $10 |
| Simvastatin | 19 | $73 | $4 |
| Lisinopril | 12 | $70 | $6 |
| Pravastatin | 11 | $65 | $6 |
2022: 12 drugs
| Telmisartan | 12 | $1,014 | $85 |
| Diclofenac | 14 | $522 | $37 |
| Atorvastatin | 40 | $448 | $11 |
| Levothyroxine | 19 | $391 | $21 |
| Alendronate | 20 | $273 | $14 |
| Pantoprazole | 16 | $244 | $15 |
| Losartan | 14 | $237 | $17 |
| Metformin | 14 | $203 | $15 |
| Amlodipine Besylate | 15 | $163 | $11 |
| Zolpidem | 11 | $131 | $12 |
| Lisinopril | 20 | $129 | $6 |
| Simvastatin | 15 | $73 | $5 |
2021: 3 drugs
| Atorvastatin | 37 | $360 | $10 |
| Lisinopril | 19 | $150 | $8 |
| Alendronate | 11 | $53 | $5 |
2020: 4 drugs
| Atorvastatin | 21 | $506 | $24 |
| Lisinopril | 20 | $130 | $7 |
| Amlodipine Besylate | 11 | $116 | $11 |
| Metformin | 16 | $103 | $6 |
2019: 4 drugs
| Atorvastatin | 13 | $255 | $20 |
| Levothyroxine | 14 | $225 | $16 |
| Lisinopril | 12 | $62 | $5 |
| Amlodipine Besylate | 12 | $47 | $4 |
Money from drug and device companies
$69 in 2022
A payment is not proof that care is biased.
| GlaxoSmithKline | Shingrix | $47 | 2 payments
|
| Pfizer | Prevnar 20 | $22 | 1 payment
|
See all 3 published payments
| GlaxoSmithKline | Meals · 2022-09-14 | Shingrix | $21 |
| GlaxoSmithKline | Meals · 2022-08-01 | Shingrix | $26 |
| Pfizer | Meals · 2022-03-22 | Prevnar 20 | $22 |
Professional record
- NPI
- 1598258154
- Licence
- CA 20A17804
- Trained
- Touro Un College of Osteopathic Medicine, Vallejo, 2018 · 8 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X); Federal specialty code 207QB0002X (207QB0002X)
- Mailing address
- 321 Middlefield Rd Ste 260, Menlo Park, CA, 94025
- NPI first listed
- 2018-06-08
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 500 W Hospital Rd, French Camp, CA, 95231 · 1300 Crane St, Menlo Park, CA, 94025